Could a patent dispute over Celgene MS hopeful ozanimod tank the BMS deal? FiercePharma
As if BMS didn’t have enough to worry about, what with major investors trying to scuttle its $74 billion Celgene buy, now a new concern has emerged—and it …
Could a patent dispute over Celgene MS hopeful ozanimod tank the BMS deal? FiercePharma
As if BMS didn’t have enough to worry about, what with major investors trying to scuttle its $74 billion Celgene buy, now a new concern has emerged—and it …